Cristina Galvez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir.

Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir.

Journal: The Journal of clinical investigation
Published: June 20, 2024

Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors.

Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors.

Journal: Med (New York, N.Y.)
Published: March 13, 2024

Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.

Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study.

Journal: The lancet. HIV
Published: November 20, 2023

Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy.

Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy.

Journal: The Journal of infectious diseases
Published: February 06, 2023

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.

Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.

Journal: Journal of virology
Published: January 31, 2023

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination.

Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccination.

Journal: EBioMedicine
Published: January 17, 2023

In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.

In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation.

Journal: Nature medicine
Published: August 05, 2022

Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA (LoViReTs).

Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA (LoViReTs).

Journal: Journal of internal medicine
Published: March 28, 2022

Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy.

Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy.

Journal: mBio
Published: November 30, 2021

Extremely low viral reservoir in treated chronically HIV-1-infected individuals.

Extremely low viral reservoir in treated chronically HIV-1-infected individuals.

Journal: EBioMedicine
Published: March 04, 2020

Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control.

Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control.

Journal: PLoS pathogens
Published: February 04, 2020

Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report.

Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report.

Journal: The lancet. HIV
Published: February 03, 2020
Showing 1-12 of 22

Last Updated: 09/26/2026